ID: ALA5279318

Max Phase: Preclinical

Molecular Formula: C20H19ClN4O8S

Molecular Weight: 510.91

Representations

Canonical SMILES:  N#CC1=C(NC[C@]2(O)O[C@H](O)[C@@H](O)[C@@H](O)[C@H]2O)Oc2[nH]c(=S)[nH]c(=O)c2C1c1ccc(Cl)cc1

Standard InChI:  InChI=1S/C20H19ClN4O8S/c21-8-3-1-7(2-4-8)10-9(5-22)16(32-17-11(10)15(29)24-19(34)25-17)23-6-20(31)14(28)12(26)13(27)18(30)33-20/h1-4,10,12-14,18,23,26-28,30-31H,6H2,(H2,24,25,29,34)/t10?,12-,13+,14-,18+,20+/m1/s1

Standard InChI Key:  DNWQRABCPKVEES-IGMJBKBHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 510.91

Molecular Weight (Monoisotopic): 510.0612

AlogP: -0.95

#Rotatable Bonds: 4

Polar Surface Area: 204.08

Molecular Species: NEUTRAL

HBA: 11

HBD: 8

#RO5 Violations: 3

HBA (Lipinski): 12

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 7.79

CX Basic pKa:

CX LogP: -0.18

CX LogD: -0.33

Aromatic Rings: 2

Heavy Atoms: 34

QED Weighted: 0.24

Np Likeness Score: -0.17

References

1. Elattar KM, El-Khateeb AY, Hamed SE..  (2022)  Insights into the recent progress in the medicinal chemistry of pyranopyrimidine analogs.,  13  (5.0): [PMID:35694689] [10.1039/d2md00076h]

Source

Source(1):

• Scientific Literature